Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_3
3
50%
Ph phase_4
2
33%

Phase Distribution

1

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 33 (50.0%)
Phase 42 (33.3%)

Trials by Status

active_not_recruiting233%
completed350%
recruiting117%

Recent Activity

3 active trials
Showing 5 of 6
completedphase_4

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

NCT06389513
completedphase_3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

NCT06700148
active_not_recruitingphase_4

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

NCT05935176
recruitingphase_1

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

NCT07203755
active_not_recruitingphase_3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

NCT06226714
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06389513Phase 4

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Completed
NCT06700148Phase 3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

Completed
NCT05935176Phase 4

Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Active Not Recruiting
NCT07203755Phase 1

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Recruiting
NCT06226714Phase 3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Active Not Recruiting
NCT06011200Phase 3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6